Ichnos Glenmark Innovation (IGI), the clinical-stage biotechnology subsidiary of Glenmark Pharmaceuticals based in New York, has announced significant progress in developing ISB 2301, an experimental therapy targeting solid tumours such as lung, breast, and colorectal cancers. This innovative drug candidate belongs to a new class of 'multispecific antibodies' that can recognize three tumour-associated markers simultaneously, aiming to activate the immune system more effectively than traditional therapies. Unlike conventional antibody drugs that target a single marker, ISB 2301 engages two types of immune cells—T cells and natural killer (NK) cells—to enhance its cancer-fighting capabilities. The company plans to submit an Investigational New Drug (IND) application by the end of 2026, with clinical studies expected to commence in 2027. Preclinical studies have indicated promising safety and pharmacokinetic data, suggesting that ISB 2301 could remain in the body long enough to exert therapeutic effects. This development follows IGI's earlier asset, ISB 2001, which garnered attention through a partnership with AbbVie, validating IGI's innovative platform technology for cancer biologics.